Gilead Sciences announced that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day.

Ma will assume responsibility for Gilead’s Pharmaceutical Development and Manufacturing organization effective July 18, 2022. Dr. Ma will succeed Dr. Yang, who is retiring from Gilead after nearly three decades.

Ma brings to her new role more than 25 years of experience in process, pharmaceutical and analytical development, quality, technical product and supply chain management, as well as global manufacturing operations. She joins Gilead from Sana Biotechnology, where she most recently served as Executive Vice President and Head of Technical Operations. Prior to Sana, Dr. Ma was the Global Head of Innovation, Manufacturing Science and Technology in Genentech/Roche’s Pharma Technical Operations.

“With more than 25 years of diverse experience, Stacey has an impressive track record in the formulation and manufacture of medicines from pre-IND through commercialization. She brings deep expertise in multiple areas and across various modalities,” said O’Day. “Under Stacey’s leadership, and as we continue to diversify our portfolio, I am confident that Gilead will maintain a global reputation for excellence in the development, manufacture and supply of medicines.”